Long Grove to market norepinephrine in sodium chloride premix injection
Long Grove Pharmaceuticals announced the strategic in-licensing of norepinephrine in 0.9% sodium chloride premix formulation from Nevakar Injectables.
This manufactured, ready-to-use formulation is room-temperature stable and will be available in three commonly administered strengths; 4 mg/250 ml (16 mcg/ml), 8 mg/250 ml (32mcg/ml), and 16 mg/250 ml (64 mcg/ml), helping strengthen what has historically been a fragile critical care supply chain.
Norepinephrine bitartrate in 0.9% sodium chloride injection is indicated to raise blood pressure in adult patients with severe, acute hypotension, and it is one of the most commonly used injectable medications in the critical care setting.
[Read more: Long Grove intros single-pack for generic Hemabate]
“Our partnership with Nevakar is aimed at helping increase the reliability related to this essential critical care product.”, said Peter Karas, chief commercial officer of Long Grove. “Norepinephrine Premix has the potential to enhance patient safety as well as our customers’ operational efficiencies by eliminating the potential risks and complications associated with compounding.”
[Read more: Long Grove Pharmaceuticals launches generic Kenalog-40]
“Nevakar has a long commitment to creating new formulations from existing molecules with the potential to improve the quality of care. Our partnership with Long Grove Pharmaceuticals helps ensure that we have a very experienced commercial team ready to successfully bring this product to market.”, said Sriram Ramanathan, CEO of Nevakar.